2 completed, 1 not yet recruiting, 1 unknown. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Not yet recruiting 1, Unknown 1 |
Follow temocillin: new trials by email Literature Review of temocillin trials Research Report on temocillin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Temocillin Compared to Standard of Care in the Treatment of Neisseria Gonorrhoeae Infections Temocillin (NEGABAN®) 2 g intravenous with lidocaine (3ml), Rectal swab for ESBL-E and microbiota (Eswab), Temocillin (NEGABAN®) 2 g intramuscular single dose with lidocaine (3ml) - Neisseria Gonorrhoeae (Ng) Infections | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 360 | 2026-09-01 | 2026-06-22 |
| Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit Piperacillin/tazobactam or temocillin, Meropenem - Sepsis, Septic Shock | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 600 | 2023-03-11 | 2023-04-18 |
| Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins Temocillin, Meropenem - Bacteremia | Phase 3 | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 334 | 2020-12-15 | 2026-01-23 |
| Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections Temocillin, meropenem or imipenem - Urinary Tract Infections | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 29 | 2019-01-04 | 2025-11-20 |
Infections (2) · Bacteremia (1) · Gonorrhea (1) · Sepsis (1) · Sexually Transmitted Diseases (1) · Shock, Septic (1) · Toxemia (1) · Urinary Tract Infections (1)
Assistance Publique - Hôpitaux de Paris (3) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1)
France (3) · Spain (1)
2017 (1), 2025 (1)